Swedish Orphan Biovitrum (Sobi) has received approval from Health Canada for an oral suspension formulation of Orfadin (nitisinone) to treat patients with hereditary tyrosinemia type 1 (HT-1).

Patients suffering from HT-1, a rare genetic disorder, have problems breaking down an amino acid called tyrosine.

This results in the formation of toxic by-products that accumulate in the body and can cause liver, renal and neurological complications, and in most cases is fatal if left untreated.

Developed by Sobi, Orfadin is the first liquid formulation nitisinone product approved in Canada and can meet the needs of small children and patients who have difficulty in swallowing capsules.

It is the first therapy approved in multiple countries worldwide for use in combination with dietary restriction of tyrosine and phenylalanine for the treatment of HT-1.

“The introduction of new nitisinone dosing options, such as Orfadin oral suspension, is the result of Sobi listening to feedback from patients and caregivers and continuing to innovate to meet their needs.”

Both Orfadin oral suspension and Orfadin 20mg capsules are currently available in Canada, in addition to the original 2mg, 5mg and 10mg capsules.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sobi Canada vice-president and general manager Bob McLay said: “The introduction of new nitisinone dosing options, such as Orfadin oral suspension, is the result of Sobi listening to feedback from patients and caregivers and continuing to innovate to meet their needs.

“In various markets around the world where Sobi has already introduced multiple innovative Orfadin formulations such as Orfadin oral suspension and Orfadin 20mg capsules, we have seen patients increasingly choose these dosing options over the first generation capsule, so we are excited to offer a choice to patients in Canada as well.”

The original approval of the Sobi treatment in Canada was based on a multinational, uncontrolled, open-label trial carried out on a total of 291 patients with HT-1.